Overview

A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer

Status:
Not yet recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open label Phase II neoadjuvant study comparing the efficacy and safety of the combination of traditional herbal medicine for cancer immunotherapy and neoadjuvant therapy versus neoadjuvant therapy in patients with breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Shengjing Hospital
Treatments:
Antibodies
Antibodies, Monoclonal
Carboplatin
Cyclophosphamide
Docetaxel
Epirubicin
Pertuzumab
Trastuzumab